Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Disorders?

被引:0
|
作者
Youdim, Moussa B. H. [1 ,2 ]
机构
[1] Technion Israel Inst Technol, Eve Topf & US Natl Parkinson Fdn Ctr Excellence N, Bruce Rappaport Fac Med, Haifa, Israel
[2] Yonsei Univ, Dept Biol, Seoul, South Korea
来源
RAMBAM MAIMONIDES MEDICAL JOURNAL | 2015年 / 6卷 / 03期
关键词
Rasagiline multimodal drugs; antiapoptotic; neuroprotection; neurorestoration; Parkinson's disease; Alzheimer's disease;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Parkinson's disease (PD) and Alzheimer's disease (AD) are severe neurodegenerative disorders, with no drugs that are currently approved to prevent the neuronal cell loss characteristic in brains of patients suffering from PD and AD, and all drug treatments are symptomatic and monomodal in their action. Due to the complex pathophysiology, including a cascade of neurotoxic molecular events that result in neuronal death and predisposition to depression and eventual dementia, and etiology of these disorders, an innovative approach towards neuroprotection or neurorestoration (neurorescue) is the development and use of multifunctional pharmaceuticals which can act at different brain regions and neurons. Such drugs target an array of pathological pathways, each of which is believed to contribute to the cascades that ultimately lead to neuronal cell death. In this short review, we discuss examples of novel multifunctional ligands that may have potential as neuroprotective- neurorestorative therapeutics in PD and AD, some of which are under development. The compounds discussed originate from synthetic chemistry as well as from natural sources.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Traditional Chinese medicine-based neurorestorative therapy for Alzheimer's and Parkinson's disease
    Zhang, Zhu
    Zhang, Shiqing
    Lui, Cathy Nga-Ping
    Zhu, Peili
    Zhang, Zhang
    Lin, Kaili
    Dai, Yiwu
    Yung, Ken Kin-Lam
    JOURNAL OF NEURORESTORATOLOGY, 2019, 7 (04): : 207 - 222
  • [32] Do we still need animals? Surveying the role of animal-free models in Alzheimer's and Parkinson's disease research
    Aerts, Liesbeth
    Miccoli, Beatrice
    Delahanty, Aaron
    Witters, Hilda
    Verstraelen, Sandra
    De Strooper, Bart
    Braeken, Dries
    Verstreken, Patrik
    EMBO JOURNAL, 2022, 41 (06):
  • [33] Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
    Amit, Tamar
    Avramovich-Tirosh, Yael
    Youdim, Moussa B. H.
    Mandel, Silvia
    FASEB JOURNAL, 2008, 22 (05): : 1296 - 1305
  • [34] Why do we need operationalized diagnosis of mental disorders?
    Freyberger, HJ
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2003, 71 (09) : 478 - 479
  • [35] Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?
    Sequeira, Lisa
    Benfeito, Sofia
    Fernandes, Carlos
    Lima, Ines
    Peixoto, Joana
    Alves, Catarina
    Machado, Claudia Sofia
    Gaspar, Alexandra
    Borges, Fernanda
    Chavarria, Daniel
    PHARMACEUTICS, 2024, 16 (06)
  • [36] Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
    dos Santos, Vanessa V.
    Rodrigues, Ana Lucia S.
    De Lima, Thereza C.
    de Barioglio, Susana R.
    Raisman-Vozari, Rita
    Prediger, Rui D.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (38) : 6773 - 6790
  • [37] Subthalamic lead placement in Parkinson's disease: Do we need microstimulation?
    Sixel-Doring, Friederike
    von Eckardstein, Kajetan
    Malinova, Vesna
    Pinter, Anabel
    Dragaescu, Cristina
    Rohde, Veit
    Trenkwalder, Claudia
    JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (05) : 669 - 669
  • [38] Biosensors for Parkinson's Disease: Where Are We Now, and Where Do We Need to Go?
    Maddocks, Grace M.
    Eisenstein, M.
    Soh, H. Tom
    ACS SENSORS, 2024, 9 (09): : 4307 - 4327
  • [39] Behcet's Syndrome Is Not So Rare: Why Do We Need to Know?
    Yazici, Hasan
    Seyahi, Emire
    Yurdakul, Sebahattin
    ARTHRITIS AND RHEUMATISM, 2008, 58 (12): : 3640 - 3643
  • [40] Why Do We Need Vitalism? Canguilhem's Reinterpretation of One Concept
    Vydra, Anton
    FILOZOFIA, 2015, 70 (01): : 13 - 22